Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study-Reference-Cited by-同舟云学术

Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study

Published:2016-04-29 Issue:6 Volume:77 Page:1245-1252
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Sekine Akimasa,Satoh Hiroaki,Baba Tomohisa,Ikeda Satoshi,Okuda Ryo,Shinohara Takeshi,Komatsu Shigeru,Hagiwara Eri,Iwasawa Tae,Ogura Takashi,Kato Terufumi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-016-3040-8.pdf

Reference43 articles.

1. King TE Jr (2005) Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med 172(3):268–279

2. Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, Nakamura Y, Inui N, Nakamura H, Chida K (2009) Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 14(5):723–728

3. Park J, Kim DS, Shim TS, Lim CM, Koh Y, Lee SD, Kim WS, Kim WD, Lee JS, Song KS (2001) Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 17(6):1216–1219

4. Raghu G, Nyberg F, Morgan G (2004) The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 91(Suppl 2):S3–10

5. Antoniou KM, Wells AU (2013) Acute exacerbations of idiopathic pulmonary fibrosis. Respir Int Rev Thorac Dis 86(4):265–274

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy;Scientific Reports;2024-05-03

2. Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition;Respiratory Investigation;2024-05

3. Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis;Cancers;2024-04-29

4. Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis;Annals of the American Thoracic Society;2024-04

5. Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia;ERJ Open Research;2024-01-11